Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May-Jun;33(3):281-6.
doi: 10.4103/0970-2113.180805.

Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study

Rahul Magazine  1 , Hameed Aboobackar Shahul  1 , Bharti Chogtu  2 , Asha Kamath  3
Affiliations

Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study

Rahul Magazine et al. Lung India. 2016 May-Jun.

Abstract

Background: Leukotriene modifiers have an established role in the management of chronic asthma but their role in acute asthma is still under evaluation.

Objective: To study and compare the effects of oral montelukast with oral zileuton in acute asthma.

Materials and methods: This study included 120 asthmatics and was conducted from September 2012 to March 2014. Patients were randomized into three different groups to receive montelukast or zileuton or placebo in addition to standard treatment for asthma exacerbation. Peak expiratory flow rate (PEFR) values, details of rescue medication and vital signs were recorded at 6 h, 12 h, 24 h, and 48 h of drug or placebo administration and at discharge. Additional recording was done in the morning (8-10 am) following admission. The primary endpoint was the mean PEFR of each group at these time points; the secondary end point being the need for rescue medications.

Results: The mean PEFR recordings of the three study groups - placebo, montelukast, and zileuton - respectively, at various time points were as follows: at 6 h (223.25 ± 90.40, 199.00 ± 82.52, 233.75 ± 84.05; P = 0.240); at 12 h (271.00 ± 109.38, 251.50 ± 101.44, 309.50 ± 129.63; P = 0.048); at 24 h (288.25 ± 114.26, 269.00 ± 107.51, 324.50 ± 127.88; P = 0.080); and at 48 h (295.00 ± 114.80, 293.50 ± 113.24, 344.75 ± 119.91; P = 0.015); discharge (305.00 ± 118.56, 305.25 ± 119.51, 361.25 ± 119.70; P = 0.010). The mean PEFR for the three study groups at 8-10 am on the morning following admission was 268.75 ± 111.43, 252.50 ± 99.99, 306.75 ± 114.44; P = 0.047. Total rescue doses needed were 10, 1, and 0, respectively (P = 0.049).

Conclusion: Zileuton is better than montelukast as an additional drug in acute asthma and results in significant improvement in lung function, and reduction in the need for rescue medications.

Keywords: Acute asthma; montelukast; zileuton.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean peak expiratory flow rate at different time points after initiation of treatment (with baseline peak expiratory flow rate [167.92 l/min] set as the covariate)
See this image and copyright information in PMC

References

    1. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001;(1):CD002178. - PubMed
    1. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest. 2001;119:1533–46. - PubMed
    1. Bradshaw TA, Matusiewicz SP, Crompton GK, Innes JA, Greening AP. Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respir Med. 2008;102:143–9. - PubMed
    1. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: Systematic review and meta-analysis. Emerg Med J. 2007;24:823–30. - PMC - PubMed
    1. Porter RS, Nester, Braitman LE, Geary U, Dalsey WC. Intravenous magnesium is ineffective in adult asthma, a randomized trial. Eur J Emerg Med. 2001;8:9–15. - PubMed